Dexamethasone regulates endothelin-1 and endothelin receptors in human non-pigmented ciliary epithelial (HNPE) cells

Xinyu Zhang, Raghu Krishnamoorthy, Ganesh Prasanna, Santosh Narayan, Abbot Clark, Thomas Yorio

Research output: Contribution to journalArticleResearchpeer-review

25 Citations (Scopus)

Abstract

Endothelin-1 (ET-1) lowers intraocular pressure (IOP) in animal models by regulating aqueous humour dynamics through both inflow and outflow mechanisms. Moreover, ET's concentration is elevated in glaucoma patients and in animal models of glaucoma. Glucocorticoid therapy often can lead to increase IOP in susceptible individuals including patients with primary open angle glaucoma (POAG). In this study, we examined the effects of dexamethasone (Dex), a frequently used anti-inflammatory glucocorticoid, on the synthesis and release of endothelin-1 and on the expression of endothelin receptors in human non-pigmented ciliary epithelial (HNPE) cells, an established source for ET-1 in the anterior chamber. As measured by ET-1 immunoreactivity, ET-1 was concentration-dependently increased following 24hr Dex treatment, with a maximum concentration (100nM) causing a threefold increase of ET-1 release. Western blot analysis of HNPE cells showed the expression of endothelin receptor A (ETA) and endothelin receptor B (ETB) with approximate molecular weights of 40kDa. Dex treatment decreased ETA receptor expression at all Dex doses, but up-regulated ETB receptors with 10nM Dex having the greatest effect. Quantitative PCR demonstrated that Dex also increased the mRNA of pre-pro-ET-1 (ppET-1) and ETB but decreased the mRNA of ETA. RU486, a glucocorticoid receptor antagonist, was able to block Dex's actions on ET release and ETB receptor expression, but did not block its action on ETA receptor expression. Endothelin receptors were minimally expressed in HNPE cells as determined in binding experiments (Bmax: ETA 17, ETB 25fmolmg-1 membrane protein). However Dex treatment stimulated a dramatic increase in ETB receptor density while decreasing ETA receptors (Bmax: ETA 11, ETB 116fmolmg-1 membrane protein). The regulation of endothelin and its receptors could be a novel mechanism associated with glucocorticoid's effects on intraocular pressure. The increase in ET-1 and disproportionate regulation in ET receptor expression by Dex could promote dysregulation in ET's mechanism on both inflow and outflow, thus affecting aqueous humour dynamics in the anterior chamber of the eye.

Original languageEnglish
Pages (from-to)261-272
Number of pages12
JournalExperimental eye research
Volume76
Issue number3
DOIs
StatePublished - 1 Mar 2003

Fingerprint

Endothelin A Receptors
Endothelin Receptors
Dexamethasone
Endothelin B Receptors
Endothelin-1
Epithelial Cells
Intraocular Pressure
Glucocorticoids
Aqueous Humor
Anterior Chamber
Glaucoma
Membrane Proteins
Animal Models
Messenger RNA
Glucocorticoid Receptors
Therapeutics
Anti-Inflammatory Agents
Molecular Weight
Western Blotting
Polymerase Chain Reaction

Keywords

  • Aqueous humour dynamics
  • Ciliary epithelium
  • Dexamethasone
  • Endothelin receptor A
  • Endothelin receptor B
  • Endothelin-1
  • Glucocorticoid receptor
  • Intraocular pressure
  • RU486

Cite this

@article{eba490d60c7c4d38a21a01e430ced644,
title = "Dexamethasone regulates endothelin-1 and endothelin receptors in human non-pigmented ciliary epithelial (HNPE) cells",
abstract = "Endothelin-1 (ET-1) lowers intraocular pressure (IOP) in animal models by regulating aqueous humour dynamics through both inflow and outflow mechanisms. Moreover, ET's concentration is elevated in glaucoma patients and in animal models of glaucoma. Glucocorticoid therapy often can lead to increase IOP in susceptible individuals including patients with primary open angle glaucoma (POAG). In this study, we examined the effects of dexamethasone (Dex), a frequently used anti-inflammatory glucocorticoid, on the synthesis and release of endothelin-1 and on the expression of endothelin receptors in human non-pigmented ciliary epithelial (HNPE) cells, an established source for ET-1 in the anterior chamber. As measured by ET-1 immunoreactivity, ET-1 was concentration-dependently increased following 24hr Dex treatment, with a maximum concentration (100nM) causing a threefold increase of ET-1 release. Western blot analysis of HNPE cells showed the expression of endothelin receptor A (ETA) and endothelin receptor B (ETB) with approximate molecular weights of 40kDa. Dex treatment decreased ETA receptor expression at all Dex doses, but up-regulated ETB receptors with 10nM Dex having the greatest effect. Quantitative PCR demonstrated that Dex also increased the mRNA of pre-pro-ET-1 (ppET-1) and ETB but decreased the mRNA of ETA. RU486, a glucocorticoid receptor antagonist, was able to block Dex's actions on ET release and ETB receptor expression, but did not block its action on ETA receptor expression. Endothelin receptors were minimally expressed in HNPE cells as determined in binding experiments (Bmax: ETA 17, ETB 25fmolmg-1 membrane protein). However Dex treatment stimulated a dramatic increase in ETB receptor density while decreasing ETA receptors (Bmax: ETA 11, ETB 116fmolmg-1 membrane protein). The regulation of endothelin and its receptors could be a novel mechanism associated with glucocorticoid's effects on intraocular pressure. The increase in ET-1 and disproportionate regulation in ET receptor expression by Dex could promote dysregulation in ET's mechanism on both inflow and outflow, thus affecting aqueous humour dynamics in the anterior chamber of the eye.",
keywords = "Aqueous humour dynamics, Ciliary epithelium, Dexamethasone, Endothelin receptor A, Endothelin receptor B, Endothelin-1, Glucocorticoid receptor, Intraocular pressure, RU486",
author = "Xinyu Zhang and Raghu Krishnamoorthy and Ganesh Prasanna and Santosh Narayan and Abbot Clark and Thomas Yorio",
year = "2003",
month = "3",
day = "1",
doi = "10.1016/S0014-4835(02)00323-8",
language = "English",
volume = "76",
pages = "261--272",
journal = "Experimental Eye Research",
issn = "0014-4835",
publisher = "Academic Press Inc.",
number = "3",

}

Dexamethasone regulates endothelin-1 and endothelin receptors in human non-pigmented ciliary epithelial (HNPE) cells. / Zhang, Xinyu; Krishnamoorthy, Raghu; Prasanna, Ganesh; Narayan, Santosh; Clark, Abbot; Yorio, Thomas.

In: Experimental eye research, Vol. 76, No. 3, 01.03.2003, p. 261-272.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Dexamethasone regulates endothelin-1 and endothelin receptors in human non-pigmented ciliary epithelial (HNPE) cells

AU - Zhang, Xinyu

AU - Krishnamoorthy, Raghu

AU - Prasanna, Ganesh

AU - Narayan, Santosh

AU - Clark, Abbot

AU - Yorio, Thomas

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Endothelin-1 (ET-1) lowers intraocular pressure (IOP) in animal models by regulating aqueous humour dynamics through both inflow and outflow mechanisms. Moreover, ET's concentration is elevated in glaucoma patients and in animal models of glaucoma. Glucocorticoid therapy often can lead to increase IOP in susceptible individuals including patients with primary open angle glaucoma (POAG). In this study, we examined the effects of dexamethasone (Dex), a frequently used anti-inflammatory glucocorticoid, on the synthesis and release of endothelin-1 and on the expression of endothelin receptors in human non-pigmented ciliary epithelial (HNPE) cells, an established source for ET-1 in the anterior chamber. As measured by ET-1 immunoreactivity, ET-1 was concentration-dependently increased following 24hr Dex treatment, with a maximum concentration (100nM) causing a threefold increase of ET-1 release. Western blot analysis of HNPE cells showed the expression of endothelin receptor A (ETA) and endothelin receptor B (ETB) with approximate molecular weights of 40kDa. Dex treatment decreased ETA receptor expression at all Dex doses, but up-regulated ETB receptors with 10nM Dex having the greatest effect. Quantitative PCR demonstrated that Dex also increased the mRNA of pre-pro-ET-1 (ppET-1) and ETB but decreased the mRNA of ETA. RU486, a glucocorticoid receptor antagonist, was able to block Dex's actions on ET release and ETB receptor expression, but did not block its action on ETA receptor expression. Endothelin receptors were minimally expressed in HNPE cells as determined in binding experiments (Bmax: ETA 17, ETB 25fmolmg-1 membrane protein). However Dex treatment stimulated a dramatic increase in ETB receptor density while decreasing ETA receptors (Bmax: ETA 11, ETB 116fmolmg-1 membrane protein). The regulation of endothelin and its receptors could be a novel mechanism associated with glucocorticoid's effects on intraocular pressure. The increase in ET-1 and disproportionate regulation in ET receptor expression by Dex could promote dysregulation in ET's mechanism on both inflow and outflow, thus affecting aqueous humour dynamics in the anterior chamber of the eye.

AB - Endothelin-1 (ET-1) lowers intraocular pressure (IOP) in animal models by regulating aqueous humour dynamics through both inflow and outflow mechanisms. Moreover, ET's concentration is elevated in glaucoma patients and in animal models of glaucoma. Glucocorticoid therapy often can lead to increase IOP in susceptible individuals including patients with primary open angle glaucoma (POAG). In this study, we examined the effects of dexamethasone (Dex), a frequently used anti-inflammatory glucocorticoid, on the synthesis and release of endothelin-1 and on the expression of endothelin receptors in human non-pigmented ciliary epithelial (HNPE) cells, an established source for ET-1 in the anterior chamber. As measured by ET-1 immunoreactivity, ET-1 was concentration-dependently increased following 24hr Dex treatment, with a maximum concentration (100nM) causing a threefold increase of ET-1 release. Western blot analysis of HNPE cells showed the expression of endothelin receptor A (ETA) and endothelin receptor B (ETB) with approximate molecular weights of 40kDa. Dex treatment decreased ETA receptor expression at all Dex doses, but up-regulated ETB receptors with 10nM Dex having the greatest effect. Quantitative PCR demonstrated that Dex also increased the mRNA of pre-pro-ET-1 (ppET-1) and ETB but decreased the mRNA of ETA. RU486, a glucocorticoid receptor antagonist, was able to block Dex's actions on ET release and ETB receptor expression, but did not block its action on ETA receptor expression. Endothelin receptors were minimally expressed in HNPE cells as determined in binding experiments (Bmax: ETA 17, ETB 25fmolmg-1 membrane protein). However Dex treatment stimulated a dramatic increase in ETB receptor density while decreasing ETA receptors (Bmax: ETA 11, ETB 116fmolmg-1 membrane protein). The regulation of endothelin and its receptors could be a novel mechanism associated with glucocorticoid's effects on intraocular pressure. The increase in ET-1 and disproportionate regulation in ET receptor expression by Dex could promote dysregulation in ET's mechanism on both inflow and outflow, thus affecting aqueous humour dynamics in the anterior chamber of the eye.

KW - Aqueous humour dynamics

KW - Ciliary epithelium

KW - Dexamethasone

KW - Endothelin receptor A

KW - Endothelin receptor B

KW - Endothelin-1

KW - Glucocorticoid receptor

KW - Intraocular pressure

KW - RU486

UR - http://www.scopus.com/inward/record.url?scp=0037374514&partnerID=8YFLogxK

U2 - 10.1016/S0014-4835(02)00323-8

DO - 10.1016/S0014-4835(02)00323-8

M3 - Article

VL - 76

SP - 261

EP - 272

JO - Experimental Eye Research

JF - Experimental Eye Research

SN - 0014-4835

IS - 3

ER -